2
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER_GOV
1
Study Type
Interventional
1
Sponsor
Conditions
Arthritis, Rheumatoid
8
Melanoma
6
Colitis, Ulcerative
6
Inflammatory Bowel Diseases
5
Crohn Disease
5
Carcinoma, Non-Small-Cell Lung
4
Lung Neoplasms
3
Colitis
3
Urogenital Neoplasms
2
Inflammation
2
Hematologic Neoplasms
2
Graft vs Host Disease
2
Fatigue
2
Depressive Disorder, Major
2
Depression
2
Cachexia
2
Anorexia
2
Vasculitis
1
Takayasu Arteritis
1
Syndrome
1
Stroke
1
Stevens-Johnson Syndrome
1
Spondylitis, Ankylosing
1
Skin Neoplasms
1
Recurrence
1
Rare Diseases
1
Psoriasis
1
Precancerous Conditions
1
Pemphigoid, Benign Mucous Membrane
1
Pancreatic Neoplasms
1
Interventions
Cyclophosphamide
153
Dexamethasone
141
Rituximab
85
fludarabine
79
Lenalidomide
72
Cytarabine
70
Bortezomib
64
fludarabine phosphate
63
Gemcitabine
62
venetoclax
54
Etoposide
53
pomalidomide
52
pembrolizumab
52
Paclitaxel
48
Cisplatin
48
Carboplatin
48
Peripheral Blood Stem Cell Transplantation
47
Filgrastim
40
Radiotherapy
39
Busulfan
37
Calcium Dobesilate
36
Methotrexate
34
Melphalan
34
Bevacizumab
33
carfilzomib
32
Cyclosporine
32
Azacitidine
32
Mycophenolic Acid
30
Vincristine
29
Bendamustine Hydrochloride
29
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recurrence
×
Infliximab
×
Clear all
NCT03011268
2025-05-31
BIOSTOP
Helse Møre og Romsdal HF
Phase NA
Completed
174 enrolled